Why Inducing (“Turning On”) the Telomerase Gene Does Not “Cause” Cancer
“We cannot solve our problems with the same level of thinking that created them.” — Albert Einstein
One of the most persistent misconceptions in modern biology is the belief that expressing telomerase in otherwise healthy somatic cells will “cause” cancer. This idea is not only misleading—it may be backwards. In many contexts, maintaining longer telomeres may actually protect cells from the chromosomal instability and genomic damage that drive cancer formation.
Telomerase does not create cancer. It removes one of the barriers that prevents damaged cells from failing—and that distinction matters.
Telomerase is not the cause of cancer—it is one of many variables in a much larger system of cellular control.
To illustrate this more clearly, consider a simple analogy:
Arguing that telomerase “causes” cancer is equivalent to arguing that oxygen “causes” fires.
Oxygen is absolutely required for fire to exist—but it is not sufficient to cause one. Fire also requires an ignition source and fuel. Without those, oxygen alone does nothing. Taken to its logical conclusion, blaming oxygen for fires would lead to an absurd outcome: eliminating oxygen would prevent fires—but it would also eliminate human life.
Oxygen does not cause fire by itself. Telomerase does not cause cancer by itself. Loss of control does.
The same flawed reasoning is often applied to telomerase.
Yes, continuous telomerase activation is required for cancer cells to become truly immortal. But it is not the initiating cause of transformation. It is a permissive factor, not a catalyst. (Actually, telomerase is not strictly necessary for cancer to occur, as approximately 15% of cancer cell types use the ALT pathway and do not express telomerase at all.)
The actual drivers of cancer are well known. These include damage to tumor suppressor genes such as p53, p21, p16, and RB; dysfunction in cell cycle regulation involving cyclins, CDKs, and checkpoint genes like ATM, ATR, CHEK1, and CHEK2; and the breakdown of apoptosis—the cell’s built-in “self-destruct” mechanisms.
For a cancer to grow and persist, additional conditions must also be met. It requires fuel in the form of nutrients delivered through tumor angiogenesis, often driven by growth factors such as VEGF. It frequently depends on immune evasion, where the body’s defense systems fail to recognize and eliminate abnormal cells—effectively allowing the “fire” to spread unchecked.
Telomerase does not create these conditions. It simply removes one constraint: the limit on cellular replication.
And importantly, removing that constraint is not inherently dangerous if the underlying system remains intact.
In fact, there is a strong argument that longer telomeres—maintained in part by telomerase activity—may enhance the body’s ability to prevent cancer. 1. Immune cells with longer telomeres are more active, more responsive, and more effective at identifying and eliminating abnormal or pre-cancerous cells. In contrast, immune cells with shortened telomeres exhibit senescent gene expression patterns and reduced functionality—they are, quite literally, less capable of doing their job. 2. Longer telomeres are more effective at maintaining chromosomal integrity, and therefore preventing the types chromosomal abnormalities that can lead to cancer.
The presence of telomerase does not create cancer. The absence of proper cellular control does.
The key point is this: telomerase immortalizes cells—no more, no less.
If an immortalized cell is healthy and retains proper cell cycle control, it remains a normal, healthy cell—just no longer limited by replicative aging. Immortality, in this context, is not pathology. It is simply extended capacity. Examples: germ cells, embryonic stem cells, and iPS stem cells all express telomerase, yet are not cancerous.
Immortality is not cancer. Loss of control is cancer.
If, however, a cell already has DNA damage, dysfunctional tumor suppressor genes, impaired apoptosis, and loss of cell cycle regulation, then it is true that telomerase expression may allow that cell to proliferate more than it otherwise would.
But that raises the real question:
Is the existence of pre-cancerous cells a reason to avoid telomerase?
No.
A common concern is not that telomerase initiates cancer, but that it could accelerate the growth of already damaged cells. While this is theoretically possible, it must be weighed against the opposing effect: maintaining telomere length reduces genomic instability, improves immune function, and preserves cellular control mechanisms. In practice, the net effect may be neutral—or even protective.
Transient telomerase expression does not convert such cells into full-blown cancer. Their growth remains constrained unless additional failures occur. For a cell to become truly cancerous and immortal, it must acquire the ability to sustain its own telomerase activity—typically through mutation of its hTERT gene—or activate alternative lengthening mechanisms such as the ALT pathway.
This is a critical distinction: temporary induction of telomerase is not the same as permanent, dysregulated expression driven by genetic mutation.
There is a fundamental difference between temporarily activating a system under control—and a system becoming permanently dysregulated due to mutation.
And this leads to the most important clarification:
Immortality is not cancer. Loss of control is cancer.
If a cell remains under proper regulatory control, it is not malignant—regardless of its replicative potential. (Embryonic stem cells can be immortal without being cancerous.)
Which means that, in most practical contexts, the cancer risk associated with transient telomerase activation is negligible.
Telomerase does not create dangerous cells—it extends the lifespan of whatever cells already exist.
Importantly, telomerase activity is not foreign to human biology. It is already active in embryonic stem cells and germline cells —systems where controlled replication is essential. The question is not whether telomerase can exist safely, but how to regulate its use appropriately.
Empirical evidence further challenges the assumption that telomerase expression inherently drives cancer.
Consider lobsters. Unlike humans, lobster cells express telomerase continuously. As a result, they do not experience aging in the same dysfunctional manner typical of human biology. While lobsters eventually die from predation, injury, disease, or energetic limitations, they do not appear to succumb to the classic “diseases of aging.” Importantly, they are not prone to developing cancer—an outcome that would be expected if telomerase expression in healthy cells were a primary driver of cancer formation.
Experimental data supports this perspective.
Research led by Maria Blasco demonstrated that mice genetically engineered to express telomerase continuously did not exhibit increased cancer incidence. This finding directly contradicts the assumption that telomerase activity alone is oncogenic.
Additional support comes from our own laboratory observations. When fibroblast populations are divided into treated and untreated groups, and the treated group is exposed to telomerase-inducing molecules, a clear pattern emerges over extended population doublings. As the untreated control group approaches replicative senescence at the Hayflick limit, it exhibits a higher rate of apparent transformation compared to the treated population.
This suggests that maintaining telomere length may not increase cancer risk—but may instead reduce it by preserving genomic stability over time.
Short telomeres create instability. Stability—not limitation—is what prevents cancer.
Returning to the earlier analogy, no one would propose eliminating oxygen in order to prevent fires. Doing so would solve the wrong problem—and create a far worse one.
The same logic applies here. Eliminating or suppressing telomerase to reduce cancer risk is not only misguided—it is counterproductive to achieving long-term health and longevity.
The correct approach is not to remove essential biological functions, but to manage and control failure states when they arise.
In the case of fire, we developed methods to detect, contain, and extinguish it. In the case of cancer, the parallel is clear: develop better ways to detect, target, and eliminate malignant cells.
We are already moving in that direction. Modern cancer immunotherapies are demonstrating that the immune system can be harnessed to identify and destroy cancer cells with increasing precision and, in many cases, tolerable side effects.
And this is just the beginning.
As our understanding of cancer biology improves, so too will our ability to intervene effectively. The trajectory is not toward inevitability—but toward control.
The goal is not to eliminate the conditions of life to avoid disease—but to understand and control disease within those conditions.
In addition, there is a strong argument that longer telomeres—maintained indirectly through telomerase activity—may actually protect cells from cancerous transformation.
There is substantial evidence that chromosomes with critically short telomeres become structurally unstable, or “fragile.” This fragility increases susceptibility to exactly the kinds of genomic instability that drive cancer: DNA damage, chromosomal rearrangements, translocations, and loss of function in key tumor suppressor and cell cycle regulatory genes.
Short telomeres do not merely limit replication. They increase instability.
In other words, short telomeres do not simply limit replication—they create conditions where genetic errors are more likely to occur. The idea that long telomeres may support cancer and that short telomeres impede it is exactly backwards. Long telomeres maintain chromosomal stability, while short telomeres permit, or even encourage, chromosomal damage.
A clinical example reinforces this point. The congenital disorder dyskeratosis congenita is characterized by deficient telomerase function and critically short telomeres. Despite this lack of telomerase activity, individuals with this condition have a significantly elevated risk of cancer compared to the general population.
This runs directly counter to the conventional assumption that telomerase activity promotes cancer. In this context, the absence of telomerase—and the resulting telomere dysfunction—appears to increase cancer susceptibility.
Taken together, these observations suggest that maintaining telomere length may reduce the likelihood of cancerous transformation by preserving genomic stability over time.
Which leads to an important implication:
Transient activation of telomerase may, on balance, prevent as many—or potentially more—instances of cancer than it could temporarily support.
While this hypothesis is increasingly supported by existing data, further research is needed to fully quantify and validate the effect.
Telomere dysfunction creates risk. Stability—not limitation—is what protects the genome.
A natural follow-up question is: if telomerase is beneficial, why isn’t it expressed constitutively in most human cells?
If telomerase extends cellular lifespan, why would natural selection “turn it off?”
One common explanation is that repressing telomerase evolved as a cancer prevention mechanism. But there is a simpler—and likely more accurate—explanation:
There was no selective pressure for long-lived cells.
Natural selection does not optimize for long-term health or lifespan. It optimizes for reproductive success. Once an organism has successfully reproduced, there is minimal evolutionary pressure to maintain long-term cellular integrity.
For most species, survival advantages were tied to relatively rapid life cycles—birth, maturation, reproduction, and death. Shorter generational turnover allows populations to adapt more quickly to changing environments, providing a strong evolutionary advantage. Telomere length and telomerase expression were therefore “tuned” just enough to support successful reproduction—not indefinite cellular maintenance.
If there had been strong selective pressure for organisms to reproduce later in life, we might expect to see very different biology—either constitutive telomerase expression or significantly longer baseline telomeres. But in a competitive and rapidly changing environment, species with slower reproductive cycles would likely have been outcompeted.
The result is the biology we observe today: most somatic cells do not express telomerase continuously.
However, this evolutionary framework applies far less to modern humans.
Humans no longer rely solely on genetic evolution to adapt to their environment. We adapt through knowledge, technology, and culture—on timescales far faster than genetic mutation. In many ways, we have already begun shifting from passive, “accidental” evolution to a more directed form of adaptation.
And with the emergence of biomedical technologies such as telomerase-based therapies, we are approaching a point where we are no longer strictly bound by the biological constraints inherited from our evolutionary past.
For those who value health and longevity, that shift is not a risk. It is an opportunity.
Natural selection optimized us to reproduce—not to last. Science and technology are now giving us the option to change that.
The question is no longer whether we can influence these systems—but whether we are willing to challenge outdated assumptions that may be holding progress back.